First Department of Surgery, Laikon General Hospital, Athens University School of Medicine, 11527 Athens, Greece.
Anticancer Res. 2010 Feb;30(2):653-60.
The aim of this study was to evaluate predictors of survival in stage IV metastatic colorectal cancer (CRC).
A total of 541 patients with histologically proven metastatic CRC (UICC stage IV) were retrospectively analysed and 37 variables were tested for their potential relationship to survival.
Mean survival time was recorded at 12.8 months [95% confidence interval (CI) 12.0-13.5]. Three factors were independently associated with improved survival: combination chemotherapy, improved performance status and dermatological complications. Eight factors were independently associated with unfavorable survival: worsened performance status, C-reactive protein >5 mg/dl, anemia, anorexia, weight loss > or =10%, fatigue, hypoalbuminemia and blood transfusions.
A number of factors could be used as predictors of survival in patients with stage IV metastatic CRC. Patients who are relatively fit, have low CRP levels and tolerate combination chemotherapy appear to have a more favorable survival outcome.
本研究旨在评估 IV 期转移性结直肠癌（CRC）患者的生存预测因素。
回顾性分析了 541 例经组织学证实的转移性 CRC（UICC 分期 IV 期）患者，对 37 个变量进行了检测，以评估其与生存的潜在关系。
中位生存时间为 12.8 个月（95%置信区间 12.0-13.5）。3 个因素与生存改善独立相关：联合化疗、体力状态改善和皮肤并发症。8 个因素与不良生存独立相关：体力状态恶化、C 反应蛋白>5mg/dl、贫血、厌食、体重减轻≥10%、乏力、低白蛋白血症和输血。
许多因素可作为 IV 期转移性 CRC 患者生存的预测因素。身体状况相对较好、CRP 水平较低且能耐受联合化疗的患者，其生存结局似乎更有利。
